abstract KEYWORD INDEX cell signaling 749, 1419 cell traffiking 23, 714 central nervous system involvement 103, 1162, 1191, 1682, 1727, 1853, 1858, 2037, 2038, 2107 central sensitization 1385, 2098 cerebral angiography 2037 cerebrospinal fluid 1293 cerebrovascular disease 53, 78, 620, 1036, 1057 certolizumab pegol 718, 1517, 1805, 1806, 1832 cervical cancer 468 cervical dysplasia 468 cervical spine 102 cFMS inhibitor 289 c-fos 1469 change over time 772 channelopathy 96 chaperonin 10 441 CHB 489 cheiroarthropathy 1624 chemerin 1534 chemokines 17, 19, 22, 25, 26, 39, 167, 270, 501, 671, 675, 742, 1083, 1100, 1131, 1210, 1230, 1240, 1403, 1417, 1427, 1476, 1507, 1520, 1534, 1726, 1751, 1906, 1992, 2016, 2253 chemotaxis 17, 39, 1419 chest scan 997 chikungunya 1640, 1642 chikungunya arthritis 1549 chikungunya rheumatism 1642 child 245 childhood 2107 childhood chronic uveitis 240, 1436 childhood Sjögren’s syndrome 1907 children 1677, 1696, 2019 Chinese 1680 cholecalciferol 962 cholesterol 332, 534, 594, 933, 1058, 1072 cholinergic agonists 866 chondrocalcinosis 872, 873, 885 chondrocytes 37, 632, 633, 634, 1472, 1473, 1477, 1481, 1482, 1483, 1484, 1489, 1490, 1494, 1500, 1501, 1503, 1514, 1532, 2227 chondroitin 940 chondroitin sulfate 938 chondrolysis 215 chronic conditions 2208 chronic fatigue syndrome 804 chronic lymphocytic leukemia 2177 chronic non-bacterial osteomyelitis 241 chronic therapy 946 chronic widespread pain 646, 649 chronotherapy 392, 1123 Churg-Strauss syndrome 2020, 2025, 2034, 2043, 2203 CIA 276, 830, 1499 CIA model 286 cigarette smoking 83 CINOD 1477 circulating endothelial cells 1283 circulating endothelial progenitor cells 1283 cis-associations 1608 citrullination 1074, 1421 citrulline 1074, 2167, 2235 CLASI 1880 classification criteria 85, 208, 210, 226, 552, 659, 777, 838, 1151, 1225, 1637, 1652, 1654, 1673, 1744, 1760, 1763, 1774, 1780, 1783, 1881, 1907, 1926, 2014, 2036, 2182, 2183, 2196 clinical disease activity index (CDA)I 317 clinical manifestations 517 clinical outcomes 1396 clinical pharmacology 254 clinical practice 331 clinical practice guidelines 70, 211, 1011, 1560, 1759 clinical practice guidelines implementation 984 clinical registry 993 clinical remission 216, 290 clinical remission criteria 308 clinical research 6 clinical trials 6, 94, 125, 150, 153, 154, 157, 196, 220, 234, 328, 334, 414, 453, 518, 533, 559, 560, 566, 663, 669, 676, 706, 710, 797, 801, 814, 815, 891, 945, 946, 953, 1108, 1115, 1119, 1121, 1122, 1132, 1154, 1161, 1273, 1368, 1452, 1455, 1458, 1629, 1640, 1766, 1781, 1805, 1806, 1811, 1832, 1875, 1930, 1935, 1949, 1961, 2032, 2169 clonal 1256 clonal expansions 1069, 1604 coagulation disorder 8, 1160 cobra 311 cocaine 2013 coccidioidomycosis 1643 coccidiomycosis 415 co-expression 847 cognition 98 cognitive adaptibility 802 cognitive behavior therapy 646, 802. 1325 cognitive dysfunction 113, 1208, 1343, 1853, 1854, 1855, 2070, 2242 cohort 517, 527, 1853 cohort study 701, 1036, 1329, 1331 colchicine 147, 148, 1288, 2087 collagen 106, 279, 606, 613, 1475, 1711, 1998, 1999 collagen antibody induced arthritis 2227 collagen-induced arthritis (CIA) 277, 285, 288, 289, 635, 714, 1523, 1622, 1707, 1732 combination therapies 319, 937, 962, 1396 communication 1332, 1575 community intervention 2141 community programs 689, 2062, 2110 community-based cohort 1544 comorbidity 58, 147, 170, 184, 879, 882, 1016, 1022, 1235, 1789, 1928, 1951, 2209 comparative analysis 566 comparative effectiveness 1702, 1795 complement 263, 430, 491, 1146, 1180, 1399, 2032, 2048, 2277 complement activation 1160 complement C6 1361 complement pathways 2227 complement receptor 2 730 complement split products 866 complement system 498 complex regional pain syndrome 1703 compliance 74 complications 415, 1381 complimentary and alternative therapy 95, 1575 computed tomography (CT) 128, 136, 176, 585, 869, 1046, 1443, 1486, 1810, 2027, 2164, 2166 computer assisted assessment 1747 computerized skin score 1439 computerized tomography 1686 conceptual model 204 confirmatory factor analysis 2247 congenital heart block 656, 732, 832, 1322, 1438, 2231 connective tissue diseases 618, 704, 1026, 1212, 1223, 1635, 2005, 2040 consensus 1701 consensus formation 1702 consensus methodology 1688 consumer health information 2284 continuum <strong>of</strong> care 2282 COPCORD 66, 1551 coping skills 1027, 1211 copy number variant 250 copy number variation 1589, 2217 core competencies 1429 coronary artery calcification 459 coronary artery disease 456, 584, 1046, 1053, 1209, 1233, 1443, 1627, 1842, 2164 correlation 915 cortical 647 corticosteroids 54, 213, 451, 480, 678, 922, 943, 1235, 1276, 1277, 1292, 1311, 1453, 1561, 1566, 1567, 1626, 1649, 1859, 1879, 2037, 2045, 2225 cost 51, 238 cost development 770 cost <strong>of</strong> fracture 1540 costimulation 2189 360 2010 Program Book
cost-utility 759, 1539 couples 1324 COX inhibitors 298, 942 CPDAI 514 CPM 2076 CRAC channel 279 C-reactive protein (CRP) 86, 312, 490, 850, 919, 1304 creatine 1384 creatine kinase 915 critical care 2102 Crohn’s disease 1279, 1656 cross cultural validation 1872 CRP 148, 2258 cry<strong>of</strong>ibrinogenemia 906 cryoglobulinemia 1646, 2010, 2011, 2024, 2030, 2036, 2039, 2042, 2046, 2201 crystal-induced arthritis 144, 146, 153, 166, 873, 875, 1531, 2151 CSF1R Fms 273 CTGF 613 c-type natriuretic peptide 259 curriculum 1430 cutaneous lupus 2238 cutaneous lupus erythematosus 1198, 1699, 1880 cutaneous manifestations 1213, 1521, 1850, 1880 cutaneous vasculitis 444 cut-<strong>of</strong>f point 525 CXCL12 21 CXCL13 323, 1250 CXCL16 1417 CXCL2 1751 CXCR4 354, 622 CXCR5 1250 CXCR6 1417 cyclic citrullinated peptide 245 cyclobenzaprine 820 cyclooxygenase 633, 936, 1489 cyclophosphamide 1401, 2026 cyclosporine 874 cystatin C 1023 cytokine 2233 cytokine receptor signaling 1525 cytokines 16, 20, 25, 33, 36, 38, 77, 103, 259, 272, 275, 285, 287, 292, 366, 431, 497, 505, 619, 632, 635, 636, 638, 696, 715, 741, 856, 862, 871, 896, 1071, 1073, 1083, 1089, 1095, 1122, 1133, 1259, 1280, 1308, 1317, 1351, 1354, 1403, 1424, 1515, 1525, 1526, 1533, 1580, 1581, 1594, 1642, 1709, 1725, 1730, 1732, 1798, 1803, 1831, 1914, 1965, 1967, 1976, 1982, 1992, 1993, 2006, 2025, 2115, 2176, 2216, 2253 cytotoxic T lymphocyte 867, 1272 D dabigatran 604 dactylitis 1932 daily living 1217 damage 262, 2031, 2070 DAM-HAQ 2256 DAMPs 845 DAPSA 514 Darly arthritis 1067 DAS 1734 DAS score 1631 DAS28 73, 662, 1806 DAS28CRP 1782 DC-STAMP 521, 1492 death 72, 1166, 1378, 2157 death receptor 3 348 decision analysis 59, 759 dectin-1 1713 Delphi 2196, 2279 Delphi survey 1701 delta-BAFF 1413 demyelinating events 57 dendrimers 281 dendritic cells 293, 636, 637, 847, 849, 851, 852, 862, 863, 1116, 1139, 1150, 1252, 1424, 1661, 1714, 1715, 1716, 1816, 1981, 2217 denosumab 2157, 2161 depo provera(medroxyprogesterone acetate) 974 depression 1024, 1862, 1882 dermatomyositis 916, 920, 921, 923, 934, 1198, 1376, 1378, 1521, 1686, 1693 DEXA 974 diabetes 339, 888, 1039, 1442, 1873 diagnosis 50, 133, 532, 547, 550, 555, 558, 621, 768, 880, 899, 1090, 1186, 1254, 1289, 1339, 1359, 1571, 1637, 1644, 1647, 1656, 1740, 1757, 1760, 1783, 1855, 1881, 1915, 1918, 1926, 1931, 1950, 2180, 2181, 2183, 2246, 2261 diagnostic codes 1571 diagnostic criteria 100, 110, 111, 112, 572, 575, 658, 780, 911, 1305, 1655, 1706, 1775, 1776, 1785, 2027, 2093, 2261 diagnostic delay 558, 1921 diameter <strong>of</strong> pulmonary artery 585 diastolic dysfunction 1059 dicl<strong>of</strong>enac 954, 955 diet 888 differentiation 630, 1271, 1490 diffuse idiopathic skeletal hyperostosis (DISH) 668 digital 121 digital analysis 124 digital ulcera 1220 digital x-ray radiogrammetry (DXR) 1770 dipyridamole 2126 DIRA 260 direct costs 754 disability 173, 186, 189, 683, 686, 687, 766, 922, 975, 1044, 1217, 1321, 1349, 1383, 1563, 1750, 1768, 2057, 2060, 2069, 2138, 2139, 2143, 2256 discriminative capacity 1927 discriminatory capacity 1629 disease activity 372, 459, 1200, 1255, 1291, 1581, 1606, 1750, 1753, 1782, 1868, 1869, 1878, 1922, 2047, 2049, 2070, 2107, 2149, 2272 disease activity and therapeutic response criteria 1212 disease activity index 1759 disease activity measure 1147 disease activity score (DAS) 295, 317, 1099, 1686, 1829 disease burden 1928 disease modification 664 disease phenotype 2272 disease severity 757, 1312, 1697 disease worsening 1752, 1766, 1778 disease-modifying antirheumatic drugs 58, 60, 74, 209, 229, 412, 417, 641, 791, 1010, 1066, 2282 DKK-1 548, 629, 1491 DMARDs 52, 54, 68, 74, 81, 82, 303, 305, 306, 324, 325, 337, 338, 415, 543, 848, 991, 1047, 1110, 1255, 1640, 1796, 1805, 2204 DNA 509, 631, 2146 DNA methylation 21, 357 DNA modification 694 doctors’ preferences 68 dopamine 1089 Doppler 1754 Doppler ultrasound 567, 1004, 1162, 1322, 1632 dose optimization 1829, 2265 dose response relation 388 dose-response 1566 double strand break repair 509 doxycycline 318 DR5 1135 drug interactions 597, 801, 1575 drug levels 1825 drug safety 319 drug survival 1942 drug toxicity 2013 dry eyes and dry mouth 1901 dual energy CT scan 2152 dual energy x-ray absorptiometry (DEXA) 206, 976, 981, 1006, 1018, 1543 duloxetine 105, 175 durability clinical remission 308 duration <strong>of</strong> RA 83 dyadic coping 1324 abstract KEYWORD INDEX 2010 Program Book 361
- Page 1 and 2:
program B O O K Pre-Conference Cour
- Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
- Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
- Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
- Page 11 and 12:
the written consent of the ACR is p
- Page 13 and 14:
Shuttle Bus Service See shuttle sig
- Page 15 and 16:
ACR Resource Center Hours: Sunday,
- Page 17 and 18:
ACR Hotels + Map Complimentary shut
- Page 19 and 20:
to the premier meeting in rheumatol
- Page 21 and 22:
ACR Clinical Research Conference c/
- Page 23 and 24:
4:20 PM Germinal Center Reactions A
- Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
- Page 27 and 28:
Upon completion of this session, pa
- Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
- Page 31 and 32:
B301 Dermatological Manifestations
- Page 33 and 34:
Session Overview: The innate immune
- Page 35 and 36:
Upon completion of this session, pa
- Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
- Page 39 and 40:
and insufficiency • recall source
- Page 41 and 42:
Session Overview: The advent of bio
- Page 43 and 44:
2:45 pm 641. Major Improvements in
- Page 45 and 46:
5 University of Twente and Medisch
- Page 47 and 48:
ACR/ARHP Combined Abstract Session
- Page 49 and 50:
REF 25th Anniversary Celebration 2:
- Page 51 and 52:
5:45 PM 699. Defining Latent and/or
- Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
- Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
- Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
- Page 59 and 60:
• discuss the principles of early
- Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
- Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
- Page 65 and 66:
ACR Plenary Session II: Discovery 2
- Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
- Page 69 and 70:
Session Overview: As a clinical edu
- Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
- Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
- Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
- Page 77 and 78:
2:45 PM 1405. Development of a Visi
- Page 79 and 80:
4:30 PM Anti-citrullinated Protein
- Page 81 and 82:
of Experimental Orthopedics, Univer
- Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
- Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
- Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
- Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
- Page 91 and 92:
• compare the prevalence and epid
- Page 93 and 94:
6:45 PM Macrophage Activation Syndr
- Page 95 and 96:
Upon completion of this session, pa
- Page 97 and 98:
Session Overview: This roundtable d
- Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
- Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
- Page 103 and 104:
• describe the role of IL-1 and I
- Page 105 and 106:
Session Overview: For the clinician
- Page 107 and 108:
• identify the aspects for day-to
- Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
- Page 111 and 112:
Session Overview: Ultrasound and ma
- Page 113 and 114:
Session Overview: Fifty percent of
- Page 115 and 116:
1:20 PM Academic Rheumatology Seth
- Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
- Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
- Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
- Page 123 and 124:
Session Overview: We are witnessing
- Page 125 and 126:
Session Overview: Systemic sclerosi
- Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
- Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
- Page 131 and 132:
4:30 PM 2198. Association between V
- Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
- Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
- Page 137 and 138:
• apply these basic statistics to
- Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
- Page 141 and 142:
Immunology, Oslo University Hospita
- Page 143 and 144:
9:15 AM 2239. Factors Associated wi
- Page 145 and 146:
Upon completion of this session, pa
- Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
- Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
- Page 151 and 152:
ACR Poster Session A Cytokines, Med
- Page 153 and 154:
ACR Poster Session A 51. Associatio
- Page 155 and 156:
ACR Poster Session A 83. Respirator
- Page 157 and 158:
ACR Poster Session A 121. Bone Dens
- Page 159 and 160:
ACR Poster Session A 142. The Intra
- Page 161 and 162:
ACR Poster Session A 171. Early Pro
- Page 163 and 164:
ACR Poster Session A Pediatric Rheu
- Page 165 and 166:
ACR Poster Session A 233. Prevalenc
- Page 167 and 168:
ACR Poster Session A 266. Subtype S
- Page 169 and 170:
ACR Poster Session A 297. Body Weig
- Page 171 and 172:
ACR Poster Session A 325. Patient R
- Page 173 and 174:
ACR Poster Session A 356. Influence
- Page 175 and 176:
ACR Poster Session A 383. Efficacy
- Page 177 and 178:
ACR Poster Session A 409. Rituximab
- Page 179 and 180:
ACR Poster Session A 441. Recombina
- Page 181 and 182:
ACR Poster Session A 465. Immunoglo
- Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
- Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
- Page 187 and 188:
ACR Poster Session A 546. Prevalenc
- Page 189 and 190:
ACR Poster Session A 571. Epidemiol
- Page 191 and 192:
ACR Poster Session A 599. Validatio
- Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
- Page 195 and 196:
ACR Poster Session B 767. Economic
- Page 197 and 198:
ACR/ARHP Poster Session B 792. The
- Page 199 and 200:
ACR/ARHP Poster Session B Universit
- Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
- Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
- Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
- Page 207 and 208:
ACR/ARHP Poster Session B 935. The
- Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
- Page 211 and 212:
ACR Poster Session B 993. Early Exp
- Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
- Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
- Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
- Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
- Page 221 and 222:
ACR Poster Session B hiroshima Memo
- Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
- Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
- Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
- Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
- Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
- Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
- Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
- Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
- Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
- Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
- Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
- Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
- Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
- Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
- Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
- Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
- Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
- Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
- Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
- Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
- Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
- Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
- Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
- Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
- Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
- Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
- Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
- Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
- Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
- Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
- Page 283 and 284:
REF Industry Roundtable-supported S
- Page 285 and 286:
REF Industry Roundtable-supported S
- Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
- Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
- Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
- Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
- Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
- Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
- Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
- Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
- Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
- Page 305 and 306:
Cooper, Max D, MD Introduction . .
- Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
- Page 309 and 310:
Physical Examination Skills for Imp
- Page 311 and 312: Meroni, Pierluigi, MD Autoantibodie
- Page 313 and 314: Rogers, Joan C, PhD, OTR/ L Underst
- Page 315 and 316: Terkeltaub, Robert, MD Crystallizin
- Page 317 and 318: A Aarden, L 1825 Aarrass, S 1519, 1
- Page 319 and 320: Bakker, AAB 1095 Barendregt, B 753
- Page 321 and 322: Boutin-Le Thi Huong, D 478 Bout-Tab
- Page 323 and 324: Chatham, WW 457, 1146, 1454, 1457,
- Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
- Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
- Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
- Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
- Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
- Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
- Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
- Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
- Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
- Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
- Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
- Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
- Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
- Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
- Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
- Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
- Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
- Page 359 and 360: A α-galactosylceramide 505 A2A kno
- Page 361: Behcet’s syndrome 1284, 1288, 129
- Page 365 and 366: fibroblast like synoviocyte 27 fibr
- Page 367 and 368: impact 1063, 1325 inactive disease
- Page 369 and 370: methylation 826, 1253, 1489 methylt
- Page 371 and 372: 233, 234, 240, 243, 252, 262, 268,
- Page 373 and 374: 1599, 1600, 1603, 1605, 1606, 1609,
- Page 375 and 376: 1226, 1227, 1229, 1230, 1231, 1233,
- Page 377 and 378: Abelson, Abby Goulder, MD Education
- Page 379 and 380: Massarotti, Elena M, MD Systemic Lu
- Page 381 and 382: ACR Annual Meeting fellowS-in-train
- Page 383 and 384: NOTES 2010 Program Book 381
- Page 385 and 386: Enbrel ® (etanercept) Brief Summar
- Page 387 and 388: Prescription Enbrel ® (etanercept)